HUP0402341A2 - Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére - Google Patents

Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére

Info

Publication number
HUP0402341A2
HUP0402341A2 HU0402341A HUP0402341A HUP0402341A2 HU P0402341 A2 HUP0402341 A2 HU P0402341A2 HU 0402341 A HU0402341 A HU 0402341A HU P0402341 A HUP0402341 A HU P0402341A HU P0402341 A2 HUP0402341 A2 HU P0402341A2
Authority
HU
Hungary
Prior art keywords
cancer
treatment
ylamines
compositions containing
mammals
Prior art date
Application number
HU0402341A
Other languages
English (en)
Inventor
Kevin R. Webster
Spencer David Kimball
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HUP0402341A2 publication Critical patent/HUP0402341A2/hu
Publication of HUP0402341A3 publication Critical patent/HUP0402341A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya gyógyszerkészítmény emlősökben rák kezelésére,amely tartalmaz (1) legalább egy burjánzást gátló szert, és (2) egyáltalános képletű vegyületet vagy gyógyászatilag elfogadható sóját,ahol a képletben R1 és R2 jelentése egymástól függetlenül hidrogén-vagy fluoratom vagy alkilcsoport; R3 jelentése aril- vagyheteroarilcsoport; R4 jelentése a leírásban részletezett szervescsoport; R5 jelentése hidrogénatom vagy alkilcsoport; m értéke 0 és 2közötti egész szám; és n értéke 1 és 3 közötti egész szám. A találmánytárgya továbbá az (I) általános képletű vegyület alkalmazásaemlősökben rák kezelésére szolgáló szinergikus hatású készítményelőállítására. Ó
HU0402341A 2001-08-31 2002-08-13 Compositions containing thiazol-2-ylamines for the treatment of cancer HUP0402341A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31636901P 2001-08-31 2001-08-31
PCT/US2002/026155 WO2003020272A1 (en) 2001-08-31 2002-08-13 Compositions and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
HUP0402341A2 true HUP0402341A2 (hu) 2005-02-28
HUP0402341A3 HUP0402341A3 (en) 2005-11-28

Family

ID=23228767

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402341A HUP0402341A3 (en) 2001-08-31 2002-08-13 Compositions containing thiazol-2-ylamines for the treatment of cancer

Country Status (10)

Country Link
US (1) US20030114504A1 (hu)
EP (1) EP1429764A1 (hu)
JP (1) JP2005504065A (hu)
BG (1) BG108605A (hu)
CZ (1) CZ2004287A3 (hu)
EE (1) EE200400074A (hu)
HU (1) HUP0402341A3 (hu)
PL (1) PL368035A1 (hu)
SK (1) SK1102004A3 (hu)
WO (1) WO2003020272A1 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DE69734362T2 (de) 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1767535T3 (da) 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
ES2349532T3 (es) * 2003-02-06 2011-01-04 Bristol-Myers Squibb Company Compuestos basados en tiazolilo útiles como inhibidores de cinasa.
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
US8017321B2 (en) * 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
CA2567293C (en) 2004-05-27 2017-05-16 The Regents Of The University Of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
CN101175492B (zh) * 2005-03-11 2013-10-16 科罗拉多大学董事会 组蛋白脱乙酰酶抑制剂使癌细胞对表皮生长因子抑制剂敏感
WO2008036954A1 (en) * 2006-09-21 2008-03-27 Sunesis Pharmaceuticals, Inc. Use of n- [5- [ [ [5- (1, 1-dimethylethyl) -2-oxazoyl] methyl] thio] -2-thiazolyl] -4-piperidinecarboxamide
ES2964764T3 (es) 2008-07-29 2024-04-09 Nerviano Medical Sciences Srl Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1088049A (en) * 1975-06-03 1980-10-21 Takashi Masugi 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof
US4214852A (en) * 1978-04-20 1980-07-29 General Electric Company Variable turbine vane assembly
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
ES2384789T3 (es) * 2001-03-14 2012-07-12 Bristol-Myers Squibb Company Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas

Also Published As

Publication number Publication date
SK1102004A3 (sk) 2005-05-05
JP2005504065A (ja) 2005-02-10
CZ2004287A3 (cs) 2004-10-13
EE200400074A (et) 2004-06-15
US20030114504A1 (en) 2003-06-19
BG108605A (bg) 2005-03-31
EP1429764A1 (en) 2004-06-23
PL368035A1 (en) 2005-03-21
HUP0402341A3 (en) 2005-11-28
WO2003020272A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
HUP0301690A2 (hu) Szinergikus eljárások és készítmények rák kezelésére
HUP0402225A2 (hu) Makrolid-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0301607A2 (hu) Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0402235A2 (hu) 4,4-Difluor-1,2,3,4-tetrahidro-5H-1-benzazepin-származékok és ezek sói és ezeket tartalmazó gyógyszerkészítmények
HUP0301745A2 (hu) Ciklopentánindolok, ezeket tartalmazó gyógyszerkészítmények és a vegyületek alkalmazása
MA27040A1 (fr) Nucleosides substitues en 4'
TW200612920A (en) Novel imidazolidine derivatives
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
DE60212949D1 (de) Antivirale pyrazolopyridin verbindungen
MEP24608A (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
GEP20094675B (en) Heteroaryl- tetra-hydropiperidyl compounds useful for treating or preventing pain
HUP0401174A2 (hu) Ekteinaszcidin-analógok, alkalmazásuk rák kezelésére alkalmas gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
SE0302139D0 (sv) Novel compounds
HUP0402341A2 (hu) Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére
NO20040881L (no) Orale antidiabetes midler.
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
MXPA04006041A (es) Antivirales de piridoquinoxalina.
DE60206505D1 (de) Substituierte benzopyran derivate gegen arrhythmie
SE0101038D0 (sv) Novel compounds
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
GEP20084306B (en) Antibacterial indolone oxazolidinones, intermediates for their preparation and pharmaceutical compositions containing them
ATE274515T1 (de) Pyrazolopyridinderivate

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees